Industrial Policy & Trade Monitor· 2675 actions· ✨ 91 recent

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 3, "Several Measures of Huangpu District on Promoting Brain-Computer Interface Innovation and Transformation Services (Trial)" (informally the "BCI Service 10 Provisions"), effective 24 January 2026 and valid through 31 December 2027. The measures subsidize BCI core- technology R&D and district co-funding of national/municipal projects (up to CNY 2m, 1:1 district match), shared innovation-platform construction (up to 30% of investment, capped CNY 2m), registered medical-device commercialisation (up to 40% of R&D cost, capped CNY 5m/ year per entity), application-demonstration scenarios (up to 30% of investment, capped CNY 2m), enterprise-growth and unicorn/gazelle recognition rewards (CNY 20k-100k), industrial-park operator support (up to CNY 2m/year), equity-financing support (up to 10% of R&D cost, capped CNY 2m, for firms with ≥CNY 20m in equity funding), and international BCI conference/event sponsorship (up to 30%, capped CNY 500k).

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 2, "Several Measures on Focusing on Translational Medicine to Accelerate Industry-Medicine Integration Innovation and Development," effective 30 days after promulgation (4 February 2026 per Global Trade Alert tracking) and valid through 31 December 2027. The measures subsidize cell-and-gene therapy, mRNA, synthetic biology, regenerative medicine and digital-medicine R&D (up to CNY 2m/year per entity), platform/lab construction (up to 30% of investment, capped at CNY 2m), use of the district's translational-medicine national science facility (up to 50% of annual usage fee, capped at CNY 1m), and domestic Class 1 new-drug clinical trials (Phase I up to CNY 2m, Phase II up to CNY 5m, capped at CNY 50m/year per entity), plus annual support for biopharma industrial- park operators (up to CNY 2m/year).

On 17 September 2025 the General Office of the Shanghai Municipal People's Government issued Hufubangui [2025] No. 8, a five-year (26 September 2025 - 25 September 2030) state-aid framework to accelerate frontier-technology innovation and cultivate "future industries" across six domains — future manufacturing, future information, future materials, future energy, future space and future health. Targeted technology areas include cell and gene therapy, brain-computer interfaces, biomanufacturing, embodied intelligence (humanoid robotics/AI hardware), fourth-generation semiconductors, silicon photonics, 6G, neuromorphic computing, quantum technology, controlled nuclear fusion and regenerative medicine. Support is disbursed as tiered direct subsidies rather than tax relief, with named ceilings up to CNY 30 million per proof-of-concept/R&D platform and CNY 20 million per high-quality incubator or first-product/batch innovation award.

On 2025-09-12, Shanghai STAR Market-listed chip-equipment maker Piotech Inc. (拓荆科技, 688072.SH) disclosed a CNY 450 million (~USD 63 million) capital increase into its controlling subsidiary Piotech Jianke (Haining) Semiconductor Equipment Co., Ltd. (拓荆键科(海宁)半导体设备有限公司), which develops 3D-integration/hybrid-bonding equipment. Guotou Jixin (国投集新), a vehicle wholly owned (99.9%) by the National Integrated Circuit Industry Investment Fund Phase III ("Big Fund III"), took a 12.71% stake for roughly CNY 192 million, becoming Piotech Jianke's second-largest shareholder; Piotech's own stake fell to approximately 53.57% post-round. The round valued Piotech Jianke's pre-money equity at CNY 2.5 billion — a roughly 44x premium to its RMB 55.2 million book net-asset value as of 2024-12-31 — reflecting Big Fund III's first disclosed equity deployment since its 2024-05-24 establishment.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

On 23 July 2025 the General Office of the Shanghai Municipal People's Government issued Hufu Bangui [2025] No. 5, "Several Measures to Support Enterprises in Strengthening Basic Research and Enhancing New Momentum for High-Quality Development," effective 1 August 2025 through 31 July 2030. The measure tiers one-time subsidies of CNY 2m-10m/year to enterprises based on basic-research investment (CNY 10m-50m, 50m-100m, and 100m+ investment bands), reimburses 50% of shared scientific- equipment usage fees (capped CNY 1m/year), and grants a 100% tax deduction for corporate donations to basic research at nonprofits and universities, with integrated circuits, biomedicine and artificial intelligence named as priority participating industries.